Abstract:Renal cell carcinoma (RCC) is a common malignancy of the urinary system. Although traditional therapies, such as surgery assisted with chemotherapy have improved the quality of life and survival time of patients with RCC, patients with metastasis or recurrence benefit little from such therapies. At present, little is known about the underlying mechanisms of RCC, rendering treatment selection and implementation challenging. Therefore, investigating the cause and underlying mechanisms of RCC remain of importance to explore potential new avenues for its treatment. Inter-alpha-trypsin inhibitor heavy chain 1 (ITIH1) is an inflammation-associated gene reported to suppress the progression of liver cancer. However, its role in RCC remains poorly understood. Therefore, the present study aimed to investigate the role and mechanism of ITIH1 in RCC. Based on data obtained from The Cancer Genome Atlas database, ITIH1 expression was demonstrated to be significantly higher in tumor tissues compared with normal tissues, which was in turn negatively associated with the survival of patients with RCC. However, in RCC cells, ITIH1 was shown to be expressed at significantly lower levels compared with those in HK-2 cells. The discrepancy between tissues and cell lines might be due to the different environment of cell growth. ITIH1 knockdown in RCC cells significantly increased cell proliferation and invasion whilst significantly decreasing the apoptosis rate, compared with those in control cells (without ITIH1 knockdown). By contrast, overexpression of ITIH1 significantly inhibited cell proliferation and invasion in RCC cells. In terms of western blotting results, the phosphorylation levels of NF-kappa B were significantly increased following ITIH1 knockdown. The protein expression level of I kappa B significantly decreased whereas that of IKK, Cyclin D1, proliferating cell nuclear antigen and alpha-smooth muscle actin were significantly increased in ITIH1-knockdown cells, compared with those in the control cells (without ITIH1 knockdown). This suggests that the NF-kappa B pathway may be activated after ITIH1 knockdown. Following treatment with the NF-kappa B pathway inhibitor JSH-23 in combination with ITIH1 knockdown, RCC cell proliferation and invasion were significantly reduced compared with those after ITIH1 knockdown alone. In summary, results from the present study suggest that ITIH1 can serve an inhibitory role in the progression of RCC, which could potentially be inhibited through the NF-kappa B signaling pathway.

Research and progress of ITIH5 in tumor

Decreased ITIH5 Expression is Associated with Poor Prognosis in Primary Gastric Cancer

ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migration

ITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors

ITIH5, a p53-responsive gene, inhibits the growth and metastasis of melanoma cells by downregulating the transcriptional activity of KLF4

Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: A systematic expression analysis

ITGA5 Promotes Tumor Progression through the Activation of the FAK/AKT Signaling Pathway in Human Gastric Cancer

Enhanced Expression of Interferon-Induced Protein with Tetratricopeptide Repeats 5 Promotes Migration and Invasion of Hepatocellular Carcinoma Cells

Expression of TIGIT/CD155 and Correlations with Clinical Pathological Features in Human Hepatocellular Carcinoma

Advances in research on relationship between integrin α5β1 and tumorigenicity, invasion and metastasis

An Overview on the Emerging Role of the Plasma Protease Inhibitor Protein ITIH5 as a Metastasis Suppressor

Relationship between inter-α-trypsin inhibitor heavy chain 4 and ovarian cancer

ITIH1 Suppresses Carcinogenesis in Renal Cell Carcinoma Through Regulation of the NF‑κB Signaling Pathway

Expression and Prognostic Analyses of ITGA3, ITGA5, and ITGA6 in Head and Neck Squamous Cell Carcinoma

ITGA5 is associated with prognosis marker and immunosuppression in head and neck squamous cell carcinoma

ITGA5 promotes tumor angiogenesis in cervical cancer

ITGA5 Inhibition in Pancreatic Stellate Cells Re-Educates the in Vitro Tumor-Stromal Crosstalk

Role of interferon-induced transmembrane protein family in cancer progression: a special focus on pancreatic cancer

ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas

High Expression of ITGA3 Promotes Proliferation and Cell Cycle Progression and Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma

m6A-Dependent ITIH1 Regulated by TGF-β Acts as a Target for Hepatocellular Carcinoma Progression